Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
5.24
-0.34 (-6.09%)
At close: Dec 5, 2025, 4:00 PM EST
5.00
-0.24 (-4.58%)
After-hours: Dec 5, 2025, 5:06 PM EST
IMDX Employees
As of December 31, 2024, Insight Molecular Diagnostics had 49 total employees, including 46 full-time and 3 part-time employees. The number of employees increased by 3 or 6.52% compared to the previous year.
Employees
49
Change (1Y)
3
Growth (1Y)
6.52%
Revenue / Employee
$89,837
Profits / Employee
-$1,240,367
Market Cap
150.20M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMDX News
- 25 days ago - Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch - GlobeNewsWire
- 4 weeks ago - iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week - GlobeNewsWire
- 7 weeks ago - iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewsWire
- 2 months ago - iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring - GlobeNewsWire
- 2 months ago - Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando - GlobeNewsWire
- 3 months ago - Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database - GlobeNewsWire
- 3 months ago - IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - GlobeNewsWire